Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control

Summary

Platelet-rich plasma was prepared from 47 patients with noninsulin-dependent diabetes treated with glibenclamide and metformin, and 21 controls. The release of radio-labelled 5-hydroxy-tryptamine in response to aggregating agents (adenosine diphosphate, adrenaline and sodium arachidonate), and the effects on release of a selective thromboxane inhibitor (UK-34787) were investigated. Subsequently, 20 of the diabetic subjects were chosen at random for treatment with insulin; the remainder continued to take tablets. Platelet studies were then repeated, in all patients, after 4 and 6 months.

The results showed an association between platelet behaviour and the presence of vascular complications, and were consistent with previous observations of reduced platelet reactivity in patients taking sulphonylureas. There was no correlation of platelet reactivity with blood glucose, glycosylated haemoglobin or lipid levels.

Keywords

Non-insulin-dependent diabetes mellitus - Platelet reactivity - Sulphonylureas - Vascular complications of diabetes

• References

• 1 Shaw S, Pegrum GD, Wolff S, Ashton WL. Platelet adhesiveness in diabetes mellitus. J Clin Pathol 1967; 20: 845-847
• 2 Mayne EE, Bridges JM, Weaver JA. Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. Diabetologia 1970; 6: 436-440
• 3 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WR S, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966
• 4 Sharma SC. Platelet adhesiveness, plasma fibrinogen, and fibrinolytic activity in juvenile-onset and maturity-onset diabetes mellitus. J Clin Pathol 1981; 34: 501-503
• 5 Breddin K. Experimental and clinical investigations on the adhesion and aggregation of human platelets. Exp Biol Med 1968; 3: 14-23
• 6 Szirtes M. Platelet aggregation in diabetes mellitus. Adv Cardiol 1970; 4: 179-186
• 7 Heath H, Brigden W, Canever JV, Pollock J, Hunter PR, Kelsey J, Bloom A. Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 1971; 7: 308-315
• 8 Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-246
• 9 O,Malley BC, Timperley WR, Ward JD, Porter NR, Preston FE. Platelet abnormalities in diabetic peripheral neuropathy. Lancet 1975; 2: 1274-1276
• 10 Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975; 82: 733-738
• 11 Colwell JA, Halushka PV, Sarji K, Levine J, Sagel J, Nair RM G. Altered platelet function in diabetes mellitus. Diabetes 1976; 25 (Suppl. 02) 826-831
• 12 Fleischman AI, Bierenbaum ML, Stier A, Somol H, Watson PB. In vivo platelet function in diabetes mellitus. Thromb Res 1976; 9: 467-471
• 13 Gensini GF, Abbate R, Favilla S, Neri Serneri GG. Changes of platelet function and blood clotting in diabetes mellitus. Thromb Haemostas 1979; 42: 983-993
• 14 Porta M, Peters AM, Cousins SA, Cagliero E, FitzPatrick ML, Kohner EM. A study of platelet-relevant parameters in patients with diabetic microangiopathy. Diabetologia 1983; 25: 21-25
• 15 Jones RL, Paradise C, Peterson CM. Platelet survival in patients with diabetes mellitus. Diabetes 1981; 30: 486-489
• 16 Tindall H, Paton RC, Zuzel M, McNicol GP. Platelet life-span in diabetics with and without retinopathy. Thromb Res 1981; 21: 641-648
• 17 Burrows AW, Chaviij SI, Hockaday TD R. Plasma-thromboglobulin concentrations in diabetes mellitus. Lancet 1978; 1: 235-237
• 18 Preston FE, Ward JD, Marcola BH, Porter NR, Timperley WR, O,Malley BC. Elevated beta-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet 1978; 1: 238-240
• 19 Borsey DQ, Dawes J, Fraser DM, Prowse CV, Elton RA, Clarke BF. Plasma beta-thromboglobulin in diabetes mellitus. Diabetologia 1980; 18: 353-357
• 20 Rasi V, Ikkala E, Hekali R, Myllyla G. Factors affecting plasma beta-thromboglobulin in diabetes mellitus. Med Biol 1980; 58: 269-272
• 21 Elving LD, Casparie AF, Miedema K, Russchen CJ. Plasma beta-thromboglobulin in diabetics with and without microangiopathic complications. Diabetologia 1981; 21: 160-161
• 22 Halushka PV, Lurie D, Colwell JA. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N Engl J Med 1977; 297: 1306-1310
• 23 Ziboh VA, Maruta H, Lord J, Cagle WD, Lucky W. Increased biosynthesis of thromboxane A2 by diabetic platelets. Eur J Clin Invest 1979; 9: 223-228
• 24 Butkus A, Skrinska VA, Schumacher OP. Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb Res 1980; 19: 211-223
• 25 Lagarde M, Burtin M, Berciaud P, Blanc M, Velardo B, Dechavanne M. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. Thromb Res 1980; 19: 823-830
• 26 Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87-96
• 27 Halushka PV, Mayfield R, Wohltmann HJ, Rogers RC, Goldberg AK, McCoy SA, Loadholt CB, Colwell JA. Increased platelet arachidonic acid metabolism in diabetes mellitus. Diabetes 1981; 30 (Suppl. 02) 44-48
• 28 Colwell JA, Nair RM G, Halushka PV, Rogers C, Whetsell A, Sagel J. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979; 28 (Suppl. 01) 394-400
• 29 Heller SR, Tattersall RB. Does diabetic control matter?. Primary Care 1983; 10: 553-563
• 30 Bedi HK, Vyas BR, Bomb BS, Agarwal ML, Bedi T. Platelet adhesiveness in cases of diabetes mellitus before and after antidiabetic drugs. J Assoc Physicians India 1976; 24: 645-648
• 31 Klaff LJ, Kernoff L, Vinik AI, Jackson WP U, Jacobs P. Sulfonylureas and platelet function. Am J Med 1981; 70: 627-630
• 32 Paton RC, Kernoff PB A, Wales JK, McNicol GP. Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics. Br Med J 1981; 283: 1018-1020
• 33 Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 1. Drugs 1981; 22: 211-245
• 34 Heptinstall S, Mulley GP, Taylor PM, Mitchell JR A. Platelet-release reaction in myocardial infarction. Br Med J 1980; 280: 80-81
• 35 Mulley GP, Heptinstall S, Taylor PM, Mitchell JR A. ADP-induced platelet release reaction in acute stroke. Thromb Haemostas 1983; 50: 524-526
• 36 Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?. Br Med J 1984; 288: 1956-1959
• 37 Petersen HD, Gormsen J. Platelet aggregation in diabetes mellitus. Acta Med Scand 1978; 203: 125-130
• 38 Corbella E, Miragliotta G, Masperi R, Villa S, Bini A, de Gaetano G, Chiumello G. Platelet aggregation and antithrombin III levels in diabetic children. Haemostasis 1979; 8: 30-37
• 39 Kazmier FJ, Bowie EJ W, O,Fallon WM, Zimmerman BR, Osmundson PJ, Palumbo PJ. A prospective study of peripheral occlusive arterial disease in diabetes. IV. Platelet and plasma functions. Mayo Clin Proc 1981; 56: 243-253
• 40 Heptinstall S, Be van J, Cockbill S, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthesis on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
• 41 Heptinstall S, Fox SC. Human blood platelet behaviour after inhibition of thromboxane synthetase. Br J Clin Pharmac 1983; 15: 31S-37S
• 42 Heptinstall S, Bienz N, Cockbill SR, Hanley SP, Peacock I. Different effects of thromboxane synthetase inhibitions on platelets from different individuals. Lancet 1982; i: 1156
• 43 Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthetase inhibition by increasing the formation of prostaglandin D₂ . Biochem Pharmacol 1984; 33: 2083-2088
• 44 Bertelé V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, De Gaetano G. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. Blood 1984; 6: 1460-1466
• 45 Bertelé V, Falanga A, Tomasiak M, Cerletti C, De Gaetano G. SQ 22536, an adenylate-cyclase inhibitor, prevents the anti-platelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Thromb Haemostas 1984; 51: 125-128
• 46 Lecompte T, Joiissemet M, Hainaut J. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to thromboxane-synthetase inhibitors: involvement of cyclic-AMP. Thromb Res 1984; 35: 91-97
• 47 Sills T, Heptinstall S. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thromb Haemostas 1986; 55: 305-308
• 48 Porta M, Hilgard P, Kohner EM. Platelet shape change abnormalities in diabetic retinopathy. Diabetologia 1980; 18: 217-221
• 49 Ewald U, Kobbah M, Vessby B, Tuvemo T. Increased platelet aggregability in diabetic children: relation to serum lipid and fatty acid composition. Diabetologia 1983; 25: 382-385
• 50 Juhan I, Vague P, Buonocore M, Moulin JP, Jouve R, Vialettes B. Abnormalities of erythrocyte deformability and platelet aggregation in insulin-dependent diabetics corrected by insulin in vivo and in vitro. Lancet 1982; 1: 535-537
• 51 McDonald JW, Dupre J, Rodger NW, Champion MC, Webb CD, Ali M. Comparison of platelet thromboxane synthesis in diabetic patients on conventional insulin therapy and continuous insulin infusions. Thromb Res 1982; 28: 705-712
• 52 Jackson CA, Greaves M, Boulton AJ M, Ward JD, Preston FE. Near-normal glycaemic control does not correct abnormal platelet reactivity in diabetes mellitus. Clin Sci 1984; 67: 551-555